ProQR Therapeutics receives CTA for AX-0810, initiates Phase 1 study.

• ProQR Therapeutics receives CTA authorization for AX-0810 trial • AX-0810 targets NTCP for cholestatic diseases • Phase 1 study to begin in healthy volunteers • Initial data expected by year-end • €106.9 million cash and cash equivalents • Runway into mid-2027 • Axiomer RNA editing technology platform